OCUL vs SGP
OCUL: Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI (axitinib) in Phase 3 for wet AMD and diabetic retinal disease, and commercial product DEXTENZA approved for post-surgical inflammation and allergic conjunctivitis. SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
Side-by-side fundamentals
| Metric | OCUL | SGP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.59 | $20.54 | |
| Market cap as of 2026-07-23 | $2.0B | $682M | |
| PEG as of 2026-07-23 | -0.23 | n/a | |
| Net margin as of 2026-07-23 | -558.2% | n/a | |
| Gross margin as of 2026-07-23 | +87.2% | n/a | |
| Operating margin as of 2026-07-23 | -575.4% | n/a | |
| ROE as of 2026-07-23 | -64.5% | -75.4% | OCUL higher |
| ROA as of 2026-07-23 | -48.4% | -68.8% | OCUL higher |
| Debt / equity as of 2026-07-23 | 0.12 | 0.00 | SGP lower |
| Revenue growth (YoY) as of 2026-07-23 | -12.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +0.3% | n/a | |
| Beta as of 2026-07-23 | 0.92 | 0.97 | |
| 1-year return as of 2026-07-22 close | -25.7% | -23.2% | SGP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.